In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Kindred Biosciences (KIN), with a price target of $9.00. The company’s shares closed last Wednesday at $4.30.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 30.2% and a 48.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
Kindred Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
See today’s analyst top recommended stocks >>
Kindred Biosciences’ market cap is currently $200.6M and has a P/E ratio of -7.90. The company has a Price to Book ratio of 2.99.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
